UroToday10d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday10d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday7h
SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Joseph A Smith, Jr. Mentorship Award Lecture. by Dr.
UroToday4d
Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy - Beyond the Abstract
Partial nephrectomy (PN) aims to preserve renal function while achieving tumor control but understanding key predictors of renal outcomes remains essential to refine surgical approaches. In our study, ...
UroToday3d
Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy?
To evaluate the detection rate for prostate cancer (PCa) performing multiparametric magnetic resonance imaging (mpMRI) fusion targeted biopsy (TPBx) combined only with ipsilateral systematic prostate ...
UroToday3d
MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer.
Male infertility is a risk factor for the development of testicular germ cell tumors. In this study, we investigated microRNA profiles in seminal plasma to identify potential noninvasive biomarkers ...
UroToday3d
Non-clear cell renal cell carcinoma narrative review: where we are in 2024.
Advances in non-clear cell renal cell carcinoma (RCC) have lagged behind clear cell RCC due to the heterogeneity and relative rarity of the disease. However, more advanced molecular and genetic ...
UroToday3d
Integrating artificial intelligence in renal cell carcinoma: evaluating ChatGPT's performance in educating patients and trainees.
OpenAI's ChatGPT is a large language model-based artificial intelligence (AI) chatbot that can be used to answer unique, user-generated questions without direct training on specific content. Large ...
UroToday3d
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
A standard of care for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Given recent improvements in NAC and the morbidity ...
UroToday3d
Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.
Tumor suppressors are well known drivers of cancer invasion and metastasis in metastatic castration sensitive prostate cancer (mCSPC). However, oncogenes are also known to be altered in this state, ...
UroToday3d
Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.
Bladder cancer is the 10th most common malignancy and carries the highest treatment cost among all cancers. The elevated cost stems from its high recurrence rate, which necessitates frequent ...
UroToday3d
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.
Active surveillance (AS) is the preferred management strategy for low-risk prostate cancer. This study aimed to evaluate the impact of Habitat Risk Score (HRS), an automated approach for mpMRI ...